Novo Nordisk Discloses Insider Share Transactions
Ticker: NONOF · Form: 6-K · Filed: Nov 14, 2024 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulation
Related Tickers: NVO
TL;DR
Novo Nordisk insiders bought/sold shares, filing shows.
AI Summary
On November 13, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is in accordance with Article 19 of Regulation No. 596/2014 on market abuse, which requires reporting of such trades.
Why It Matters
This filing provides transparency into the trading activities of company insiders, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of insider trading activity, not indicative of new risks.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- Regulation No. 596/2014 (regulation) — Governing market abuse disclosures
- November 13, 2024 (date) — Date of company announcement
FAQ
What type of transactions are being disclosed by Novo Nordisk?
The filing discloses transactions in Novo Nordisk shares by the company's board members, executives, and their associated persons.
What regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When was this company announcement made?
The company announcement was made on November 13, 2024.
Where is Novo Nordisk headquartered?
Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Does Novo Nordisk file annual reports under Form 20-F or 40-F?
Novo Nordisk indicates it files annual reports under cover of Form 20-F.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-11-14 06:00:08
Filing Documents
- f6k_111324.htm (6-K) — 25KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006354.txt ( ) — 164KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: November 13, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer